Wall Street is positive on Lyell Immunopharma Inc (LYEL). On average, analysts give Lyell Immunopharma Inc a Buy rating. The average price target is $6.8, which means analysts expect the stock to increase by 309.64% over the next twelve months. That average ranking earns Lyell Immunopharma Inc an Analyst Rating of 30, which is better than 30% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating LYEL a Buy today. Find out what this means to you and get the rest of the rankings on LYEL!